Net Cash Provided by (Used in) Operating Activities of Apimeds Pharmaceuticals US, Inc. from 31 Dec 2023 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Apimeds Pharmaceuticals US, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 31 Dec 2023 to 31 Mar 2025.
  • Apimeds Pharmaceuticals US, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2025 was $20,313, a 92% increase year-over-year.
  • Apimeds Pharmaceuticals US, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2024 was $733,526, a 17% decline from 2023.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Apimeds Pharmaceuticals US, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $20,313 +$242,787 +92% 01 Jan 2025 31 Mar 2025 10-Q 20 May 2025 2025 Q1
Q1 2024 $263,100 01 Jan 2024 31 Mar 2024 10-Q 20 May 2025 2025 Q1

Apimeds Pharmaceuticals US, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $733,526 -$105,736 -17% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $627,790 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.